Building upon this foundation, there is an urgent need to develop temporally precise, stepwise combination therapies—acute phase targeting inositol transport (DNP) synergized with immune modulation (IFN-γ) for rapid infection control, recovery phase restoring gut-brain axis homeostasis through probiotics/SCFAs while enhancing central nervous system targeting of drugs (e.g., ferroptosis inhibitors) via nanocarriers. Here, IFNG is linked to infection.